Theravance to Report Fourth Quarter and Full Year 2012 Financial Results on February 12, 2013

Theravance to Report Fourth Quarter and Full Year 2012 Financial Results on 
February 12, 2013 
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/29/13 --  Theravance,
Inc. (NASDAQ: THRX) announced today that it will release financial
results for the fourth quarter and full year ended December 31, 2012
after market close on Tuesday, February 12, 2013.  
An accompanying conference call will be held at 5:00 p.m. Eastern
Standard Time. To participate in the live call by telephone, please
dial (877) 837-3908 from the U.S., or (973) 890-8166 for
international callers. Those interested in listening to the
conference call live via the internet may do so by visiting
Theravance's web site at To listen to the live
call, please go to the web site 15 minutes prior to its start to
register, download, and install any necessary audio software.  
A replay of the conference call will be available on Theravance's web
site for 30 days through March 14, 2013. An audio replay will also be
available through 11:59 p.m. Eastern Standard Time on February 19,
2013 by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for
international callers, and entering confirmation code 85984300.  
About Theravance 
Theravance is a biopharmaceutical company with a pipeline of
internally discovered product candidates and strategic collaborations
with pharmaceutical companies. Theravance is focused on the
discovery, development and commercialization of small molecule
medicines across a number of therapeutic areas including respiratory
disease, bacterial infections, and central nervous system (CNS)/pain.
Theravance's key programs include: RELVAR(TM) or BREO(TM) (FF/VI),
ANORO(TM) (UMEC/VI) and MABA (Bifunctional Muscarinic
Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc,
and its oral Peripheral Mu Opioid Receptor Antagonist program. By
leveraging its proprietary insight of multivalency to drug discovery,
Theravance is pursuing a best-in-class strategy designed to discover
superior medicines in areas of significant unmet medical need. For
more information, please visit Theravance's web site at 
THERAVANCE(R), the Theravance logo, and MEDICINES THAT MAKE A
DIFFERENCE(R) are registered trademarks of Theravance, Inc.  
and ANORO(TM) (UMEC/VI) are
investigational medicines and are not currently approved anywhere in
the world. RELVAR(TM), BREO(TM) and ANORO(TM) are trademarks of the
GlaxoSmithKline group of companies. The use of these brand names has
not yet been approved by any regulatory authority. 
Contact Information:
Michael W. Aguiar 
Senior Vice President and Chief Financial Officer 
Press spacebar to pause and continue. Press esc to stop.